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Abstract
Background No head-to-head clinical trials have been
published comparing guanfacine extended release (GXR)
and atomoxetine (ATX): two nonstimulants approved for
the treatment of attention-deficit/hyperactivity disorder
(ADHD). However, other study designs or methods could
be used to indirectly compare these two medications.
Matching-adjusted indirect comparison (MAIC) is a recent
methodology that utilizes individual patient data (IPD)
from clinical trials for one treatment and published
aggregate data from another treatment to estimate the rel-
ative efficacy of both, providing rapid, reliable comparative
efficacy results.
Objective The aim of this study was to compare the
efficacy of GXR and ATX for the treatment of ADHD
using MAIC.
Study Design A systematic literature search was con-
ducted to identify ATX and GXR trials published through
December 2012. Studies were selected for MAIC analyses
on the basis of having comparable trial characteristics and
study designs. Summary data from selected ATX trials and
IPD from selected GXR trials were used. MAIC method-
ology ensured comparable populations: target doses for the
‘base case’ comparison were selected on the basis of
maximum effective dosage ranges from the US FDA-
approved product labels (GXR 0.09–0.12 mg/kg/day, ATX
1.2 mg/kg/day for children and adolescents weighing
B70 kg). Individuals from GXR trials were selected if they
matched inclusion/exclusion criteria from selected ATX
trials; selected GXR IPD were then re-weighted to match
the published ATX trial mean baseline characteristics and
placebo outcomes. Sensitivity analyses were conducted,
examining different dosage ranges and repeating the anal-
ysis in a larger number of trials, allowing for larger and
more heterogeneous trial populations.
Main Outcome Measure The primary outcome measure
was change in ADHD Rating Scale IV (ADHD-RS-IV)
total score.
Results Using MAIC in the base case comparison, sig-
nificantly greater reductions in mean (standard error; SE)
ADHD-RS-IV total scores from baseline to end of study
were observed in patients treated with GXR relative to
ATX [-7.0 (2.2); p \ 0.01]. Significantly greater reduc-
tions for GXR over ATX were also demonstrated for
hyperactivity/impulsivity [-3.8 (1.2); p \ 0.01] and inat-
tention [-3.2 (1.3); p \ 0.05] subscales of the ADHD-RS-
IV. Similar results were observed in MAIC sensitivity
analyses evaluating other dosage ranges and using more
heterogeneous trial populations (e.g., larger randomized
sample, broader subject weight range, additional trials).
Mean (SE) decreases in ADHD-RS-IV total scores were
greater for GXR relative to ATX when including IPD for
those administered GXR at lower than target dosage
(0.075–0.090 mg/kg/day) compared with ATX at target
dosage (1.2 mg/kg/day), with a relative improvement of
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-6.0 (2.7) (p \ 0.05). Reductions in ADHD-RS-IV total
scores were also greater for GXR in another MAIC
examining GXR at target dosage (0.09–0.12 mg/kg/day)
and a broader range of ATX dosages (including three
additional trials evaluating ATX C1.2 mg/kg/day); relative
improvement for GXR versus ATX administered at target
dosage or higher was -7.6 (1.4) (p \ 0.01).
Conclusion After adjusting for difference in baseline trial
characteristics using MAIC, GXR appears to be more
efficacious than ATX for the treatment of ADHD. Results
were consistent in a variety of dosage range comparisons
and within increasingly heterogeneous trial populations.
1 Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
common psychiatric disorder in childhood, affecting an
estimated 3–7 % of school-age children in the USA [1].
While stimulants have proven to be safe and effective first-
line therapy for most patients with ADHD [2], some
patients may have a contraindication or may be intolerant,
unresponsive, or only partially responsive to stimulant
treatment. In addition, families or patients may prefer not
to use stimulant therapy [2, 3]. For these individuals,
nonstimulant treatments may be considered as treatment
alternatives [2]. Atomoxetine (ATX; Strattera, Eli Lilly
and Company), the first nonstimulant approved in the USA
for the treatment of ADHD, is a selective norepinephrine
reuptake inhibitor indicated for use as monotherapy in
children (aged 6 years and older) and adults [4]. ATX has
also been approved for use in Canada, Mexico, and several
other countries throughout the world, including in Europe,
Asia, Australia, Africa, and Latin America. An extended-
release formulation of the selective a2A-adrenergic receptor
agonist guanfacine (GXR; Intuniv, Shire Pharmaceuticals
Inc.) became the second nonstimulant approved by the
Food and Drug Administration (FDA) for the treatment of
ADHD. GXR is indicated for use both as monotherapy and
as an adjunct to stimulant medications in children and
adolescents aged 6–17 years [5]. Recently, a third non-
stimulant, clonidine extended release (KapvayTM; Shionogi
Inc.), has also been approved by the FDA for monotherapy
and adjunctive therapy in the treatment of ADHD. At
present, GXR and clonidine extended release formulations
are only licensed for use in ADHD in the USA.
The objective of the current study was to compare the
relative efficacy of GXR and ATX as nonstimulant
monotherapies for the treatment of ADHD in children and
adolescents. While a head-to-head randomized controlled
study is generally considered the most robust method for
comparing two competing interventions, this type of study
data is rarely available given the time, expense, and
dependency on manufacturers’ incentive to conduct such a
study [6, 7]. Indeed, no head-to-head randomized con-
trolled study has been conducted to date comparing GXR
and ATX. However, there is an ever-increasing demand
from US healthcare payers for comparative evidence, or
comparative effectiveness research (CER), for competing
treatment interventions to inform treatment decisions and
shape best practices [8]. In the absence of direct compar-
isons from head-to-head randomized controlled studies,
other methods for CER can be utilized, such as an indirect
treatment comparison (ITC), mixed treatment comparison,
or meta-regression [7]. While CER typically refers to
comparative ‘effectiveness’ based on real world data, this
study examines comparative ‘efficacy’ as measured in a
controlled environment. In the absence of comparative
effectiveness or efficacy data for GXR and ATX, this
comparative efficacy analysis was conducted as part of
CER. For the purposes of this publication, we will use the
term CER to include ‘efficacy.’
Indirect treatment comparisons are made using available
data from separate clinical trials of two different treatments
in a number of ways. Traditional ITCs have well-recog-
nized limitations. Comparisons based solely on published
summary data (e.g., means), such as a naı¨ve ITC, are
subject to potential biases when only a small number of
trials are available, and the summary data being compared
may not be anchored to a common comparator or adjusted
for placebo effects. Other ITC methods that may account
for baseline differences may be subject to inconsistent
conclusions depending upon the measure of effect used
(e.g., odds ratio, relative risk) [9]. Meta-regression can be
used to adjust for trial-level factors that differ between
trials (e.g., mean age), but can be unreliable for small
numbers of trials and may be subject to ecological bias
(i.e., potential false inferences arising by using group rather
than individual patient level data) [9, 10].
When only a few studies are available for an ITC, many
of the limitations of ITC can be overcome if individual
patient data (IPD) are available for just one of the treat-
ments being compared. A recent methodology in CER,
matching-adjusted indirect comparison (MAIC) [9, 11],
leverages IPD from one treatment arm to model the
observed baseline differences between two treatments. IPD
from clinical trials for a given treatment can be re-weighted
to exactly match the summary baseline characteristics and
placebo outcomes from trials of another treatment for
which only published data are available [9, 11]. After
adjusting for the imbalance in baseline characteristics,
study outcomes can be meaningfully evaluated across tri-
als. These results can either stand on their own or be used
to inform efficient prospective trial designs by informing
power calculations. In the current analysis, available IPD
from GXR studies were re-weighted to match summary
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published data from ATX studies, allowing for a more
rapid, comparable, and likely less biased comparison of
efficacy between GXR and ATX.
2 Methods
2.1 Trial Selection and Outcomes
A systematic literature search was conducted to include con-
trolled clinical trials enrolling children and adolescents (age
B18 years) with ADHD treated with GXR or ATX in Europe,
North America, or Australia. The search was conducted in
MEDLINE, MEDLINE In-Process & Other Non-Indexed
Citations, EMBASE, PsycINFO, and the Cochrane Central
Register of Controlled Trials. In addition, online documents
(clinicaltrials.gov), published systematic reviews, meta-
analyses, and post hoc analyses were reviewed for identifi-
cation of additional studies. Primary publications written in
English and published through December 2012 were included
[keywords or Medical Subject Headings (MeSH) keywords:
(ADHD or attention-deficit hyperactivity disorder) AND
(guanfacine extended release or atomoxetine)]. Studies for
data comparison were selected if they had comparable study
characteristics based upon consistent study design (multi-
center, double-blind, randomized, placebo-controlled trials),
length of treatment, and commonly reported efficacy [ADHD
Rating Scale IV (ADHD-RS-IV) scores]. Trials were exclu-
ded on the basis of the following criteria: open-label studies;
studies focusing on ADHD subgroups (e.g., requiring certain
comorbidities; requiring the study drug to be used as a specific
line of treatment; or requiring symptom severity to be mea-
sured by scales other than the ADHD-RS-IV [e.g., Clinical
Global Impressions-Severity (CGI-S) C4 at baseline]); stud-
ies with combination/adjunctive therapy with GXR or ATX
(including combination with behavioral or educational pro-
grams); ADHD symptoms reported by teachers; age younger
than 6 years; no outcome of interest (e.g., ADHD-RS-IV
score change from baseline); no baseline ADHD-RS-IV val-
ues; or no outcome of interest for individual study arms.
A total of six trials (two GXR [12, 13] and four ATX trials
[14–17]) met inclusion criteria (Fig. 1a, b). Study design
characteristics of the selected trials are available in the Elec-
tronic Supplementary Material (Appendix 1).
6 records identified 
• Systematic reviews and meta-analyses (3) 





   – Conference abstracts/posters
   – Case reports
   – Commentaries and letters
   – Recommendations/guidelines
   – Books/chapters/addresses/bibliographies/
      biographies/lectures
• Non-systematic reviews
• Systematic reviews and meta-analysis
• Not a randomized, double-blind, placebo-controlled 
   clinical trial
• RCTs without relevant 
   – Population (adults)
   – Intervention (not extended-release guanfacine) 
   – Outcomes (missing ADHD-RS-IV total score change)
206 records identified through database searching
196 records screened after duplicates removed
10 full-text articles assessed for eligibility
2 primary publications describing 2 RCTs included
8 full-text articles excluded with reasons 
• Publication of duplicate trials (1)
• Review/meta-analysis/post-hoc analysis (4)
• Subgroups of children/adolescents with ADHD 
   population (with oppositionality or requiring symptom 
   severity measured by scales other than ADHD-RS-IV) (2)
• Combination/adjunctive therapy (guanfacine used as 
   adjunctive therapy to stimulants) (1)
aFig. 1 a Guanfacine extended-
release trial selection.
b Atomoxetine trial selection.
ADHD attention-deficit/
hyperactivity disorder, ADHD-
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The efficacy outcome analyzed was the mean change from
baseline in the ADHD-RS-IV score at the final on-treatment
assessment prior to down-titration (i.e., drug tapering). The
ADHD-RS-IV total score was evaluated as the primary end-
point; secondary endpoints included the ADHD-RS-IV
hyperactivity/impulsivity and inattention subscale scores.
2.2 Dose Selection
For the purposes of a primary base case comparison of
GXR and ATX, target doses used for comparison were
selected on the basis of the maximum recommended
effective dosages from their respective FDA-approved
labels [4, 5]. For ATX, a body weight-based daily dose of
1.2 mg/kg is considered the target for children up to 70 kg
[4]—thus, 1.2 mg/kg was chosen for the base case analysis;
although a maximum recommended daily dose is 1.4 mg/
kg, no additional benefit was demonstrated at doses
[1.2 mg/kg/day for children and adolescents weighing up
to 70 kg. Among children and adolescents weighing more
than 70 kg, the maximum recommended daily dose should
not exceed 100 mg [4]. The FDA-approved dose range of
23 records identified 
• Systematic reviews and meta-analyses (20) 





   – Conference abstracts/posters
   – Case reports
   – Commentaries and letters
   – Recommendations/guidelines
   – Books/chapters/addresses/bibliographies/
      biographies/lectures
• Non-systematic reviews
• Systematic reviews and meta-analysis
• Not a randomized, double-blind, placebo-controlled 
   clinical trial
• RCTs without relevant 
   – Population (adults)
   – Intervention (not atomoxetine) 
   – Outcomes (missing ADHD-RS-IV total score change)
2 records added from pooled-analysis to be further 
reviewed for potential trials included in the analyses
1437 records identified through database searching
1326 records screened after duplicates removed
80 full-text articles assessed for eligibility
4 primary publications describing 5 RCTs included
78 full-text articles excluded with reasons
• Publication of duplicate trials (11)
• Not placebo-controlled clinical trials (13)
• Not double-blind clinical trials (28)
• Not in Europe, North America, or Australia (3)
• Subgroups of children/adolescents with ADHD 
   population (16)
   – Requiring certain comorbidities (10)
   – Age younger than 6 (1)
   – With certain subtype of ADHD only (1)
   – Requiring certain types of response in the previous 
      ADHD treatment (1)
   – Requiring certain line of therapy (1)
   – Requiring symptom severity measured by scales 
      other than ADHD-RS-IV (2)
• Combination/adjunct therapy (atomoxetine in 
   combination with psycho-education as the 
   intervention) (1)
• Not including outcomes of interested (i.e., ADHD-RS-IV 
   score change from baseline) (3)
• Outcomes reported by teachers instead of parents/
   caregivers (1)
• Missing information to conduct MAIC (2)
   – Outcomes not reported for individual study arms) (1)
   – Baseline ADHD-RS-IV scores were not reported (1)
bFig. 1 continued
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GXR is 1–4 mg once daily [5]. In order to match the
published body weight-based ATX trial data, randomized
fixed-dose data from individuals in the selected GXR trials
were converted to body weight-based doses (also reported
in the package insert and in the published study results) [5,
12, 13]. In GXR monotherapy clinical trials, clinically
relevant improvements (e.g., in ADHD-RS-IV scores) were
observed beginning in the 0.05–0.08 mg/kg/day dose
range, with additional benefit observed at doses up to
0.12 mg/kg/day [5]. As the number of patients who
received exactly GXR 0.12 mg/kg/day based on their
weight in the selected GXR studies was too small to enable
adequate comparisons, a dosage range for the base case
analysis was expanded to 0.09–0.12 mg/kg/day range.
In both GXR monotherapy studies meeting the initial
trial selection criteria [12, 13], the target dose range of
GXR 0.09–0.12 mg/kg/day was used. Of the four ATX
studies meeting the initial trial selection, only one study
[15] included a treatment arm at the target dose of 1.2 mg/
kg/day, and therefore only this study met the additional
inclusion criteria of having a treatment dosage not
exceeding the maximum dose at which efficacy was
observed. Thus, the base case analysis was drawn from
three trials: two GXR trials (GXR administered at
0.09–0.12 mg/kg/day) [12, 13] and one ATX trial (ATX
administered at 1.2 mg/kg/day) [15].
2.3 Patient Selection
While only summary published data were available from the
ATX trials, IPD were available from both GXR trials. In
order to be included in the base case analyses, individual
patients in the GXR trials [12, 13] were required to meet the
published inclusion/exclusion criteria from the Michelson
et al. 2001 ATX trial [15]: patients had to have a baseline
symptom severity score of C1.5 standard deviations (SDs)
above age and gender normative values on the ADHD-RS-IV
total score or the hyperactivity/impulsivity or inattention
subscale scores (Fig. 2). Patients from the GXR trials were
further selected into the base case analysis cohorts on the
basis of their expected body weight-based dosing. In the
original GXR study designs, patients were randomized into
fixed dose cohorts of GXR (1–4 mg) or placebo [12, 13]. For
patients randomized to GXR, expected body weight-based
dosing was calculated on the basis of patients’ assigned GXR
dosage and baseline body weight. Similarly, the expected
body weight-based dosing was evaluated for patients ran-
domized to placebo to determine the probability of allocation
into each dosing arm (1–4 mg/day); patients were not ran-
domized to any ‘strength’ of placebo, but in order to match
them to the active arm with different treatment strengths, the
probability to receive one of the active treatments that the
placebo patients would have potentially been assigned to was
calculated. Patients randomized to placebo were excluded if,
on the basis of their body weight, they would not fit into one
of the body weight-adjusted dosing arms. Placebo groups
across GXR trials were then collapsed into one group. For the
base case analysis, this patient selection process allowed the
comparative patient groups to be as homogenous as possible
within the specified dosage ranges.
2.4 Statistical Analysis
Comparative efficacy was analyzed before and after
matching with IPD. In the unadjusted comparison (i.e.,
before matching with IPD), selected IPD that met all study
selection inclusion and exclusion criteria were pooled from
both GXR trials and compared with the summary results
from the ATX trial [15] included in the base case analysis.
Baseline characteristics and efficacy were compared for the
GXR- and ATX-treated patients: continuous baseline
variables and efficacy results were compared using Stu-
dent’s t tests, and categorical baseline variables were
compared using Chi-squared tests.
For the MAIC analyses (after matching with IPD),
patients across GXR and ATX trials were matched for age,
percentage of female patients, baseline ADHD-RS-IV
hyperactivity/impulsivity and inattention subscale scores,
percentage of inattentive and hyperactive/impulsive sub-
types, and corresponding placebo response. Individual
patients in the GXR trials were assigned weightings such
that their baseline characteristics and average placebo out-
comes (either ADHD-RS-IV total score or subscale scores)
from GXR trials exactly matched those reported for the
GXR trials(12,13) ITT population
n = 631 (325 + 306)
GXR trials study sample
(0.046–0.12 mg/kg/d and placebo)
n = 403
GXR 0.09–0.12 mg/kg/d: n = 82a
GXR 0.075–0.090 mg/kg/d: n = 46a
GXR 0.046–0.075 mg/kg/d: n = 147a
Placebo: n = 136
ADHD-RS-IV score
<1.5 SD above norm
n = 24 (19 GXR, 5 placebo)
GXR <0.046 mg/kg/d or
GXR >0.12 mg/kg/d
n = 204 (204 GXR, 0 placebo)
Excluded
Excluded
Fig. 2 Patient selection: matching inclusion/exclusion criteria. aIndi-
vidual patients could have been included in more than one dose cohort
where the dose ranges overlap. ADHD attention-deficit/hyperactivity
disorder, ADHD-RS-IV ADHD Rating Scale IV, GXR guanfacine
extended release, ITT intention-to-treat, SD standard deviation
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ATX trial. Weights were modeled as a linear combination
of all reported baseline characteristics (age, percentage of
female patients, race, weight, height, ADHD-RS-IV base-
line inattentive and hyperactivity/impulsivity subscale
scores, ADHD subtype, and disease duration), as well as
pairwise interactions, and quadratic and cubic terms based
on these measures in the GXR trials. The weights were then
estimated using linear programming to minimize the sum of
the squared weights (i.e., their deviation from uniform
weighting) under the constraints that all weights were non-
negative and that all weighted mean baseline characteristics
and placebo arm outcomes were exactly balanced between
the GXR and ATX trials. After matching, efficacy outcomes
for the re-weighted GXR-treated patients were compared
with those from the ATX trial in comparable trial popula-
tions. To assess statistical significance, a bootstrap proce-
dure was applied [18]. Patients in the GXR trials were
randomly sampled with replacement to generate 1,000
bootstrap replicates. Estimation of the weights and weigh-
ted-comparisons between GXR and ATX were repeated for
each replicate. Statistical testing was then based on two-
sample t tests with unequal variance, incorporating the
bootstrap standard errors (SEs) for GXR outcomes and
reported SEs for ATX outcomes. Two-sided statistical
significance was assessed at the a = 0.05 level.
2.5 Sensitivity Analysis
In order to test the robustness of the base case results,
sensitivity analyses were conducted. From the two GXR
studies used in the base case comparison, different cohorts
of patients receiving GXR at lower doses than the target
dose (0.075–0.090 and 0.046–0.075 mg/kg/day) were
selected and were compared with the same base case target
dose of ATX (1.2 mg/kg/day) in the three-trial sensitivity
analysis [12, 13, 15].
To determine if the base case results were generalizable
to a broader heterogeneous trial population, a second
MAIC analysis was conducted where ATX doses C1.2 mg/
kg/day were compared against three GXR dose cohorts
(0.09–0.12, 0.075–0.090, and 0.046–0.075 mg/kg/day). For
this analysis, three additional ATX trials met the selection
criteria in addition to the three trials included in the base
case (‘six-trial’ analysis). The three additional ATX trials
included in the six-trial sensitivity analysis did not report
results with a fixed 1.2 mg/kg/day ATX dosage, but rather
varied dosages of ATX (titrated up to 2 mg/kg/day)
[14, 16, 17].
Statistical evaluations for the sensitivity analyses were
conducted in a manner similar to that described for the base
case comparison.
3 Results
Baseline pooled patient characteristics for the base case
and three-trial sensitivity analyses are shown in Table 1.
Before matching, mean age between patients in the GXR
trials and ATX trials was statistically significantly differ-
ent. After matching, all means and SDs of continuous
Table 1 Baseline characteristics before and after matching in the three-trial base case and sensitivity analyses







Pre-match Post-match Pre-match Post-match Pre-match Post-match
Age, mean (SD), years 9.0 (1.8)* 11.5 (2.4) 10.9 (2.5) 11.5 (2.4) 10.1 (2.0)* 11.5 (2.4) 11.5 (2.4)
Females, % (SD) 24.4 (42.9) 28.6 (45.2) 26.5 (44.1) 28.6 (45.2) 19.6 (39.7) 28.6 (45.2) 28.6 (45.2)
ADHD subtype, % (SD)
Inattentive 18.3 (38.7) 27.4 (44.6) 26.5 (44.1) 27.4 (44.6) 23.9 (42.7) 27.4 (44.6) 27.4 (44.6)
Hyperactive-impulsive 2.4 (15.4) 1.2 (10.8) 3.4 (18.1) 1.2 (10.8) 2.2 (14.6) 1.2 (10.8) 1.2 (10.8)
Combined 79.3 (40.5) 71.4 (45.2) 70.1 (45.8) 71.4 (45.2) 73.9 (43.9) 71.4 (45.2) 71.4 (45.2)
Baseline ADHD-RS-IV outcomes, mean (SD)
Total score 40.1 (7.7) 39.2 (9.2) 38.9 (8.7) 39.2 (9.2) 39.5 (8.6) 39.2 (9.2) 39.2 (9.2)
Inattention subscale score 21.9 (3.8) 22.2 (4.0) 22.1 (4.0) 22.2 (4.0) 21.7 (4.4) 22.2 (4.0) 22.2 (4.0)
Hyperactivity/impulsivity subscale score 18.2 (5.7) 16.9 (7.1) 16.8 (6.7) 16.9 (7.1) 17.8 (6.1) 16.9 (7.1) 16.9 (7.1)
ADHD attention-deficit/hyperactivity disorder, ADHD-RS-IV ADHD Rating Scale IV, ATX atomoxetine, GXR guanfacine extended-release, SD
standard deviation
* p \ 0.05 compared with ATX
a GXR group was matched with the ATX group; therefore, the baseline characteristics of the ATX group remained the same before and after
matching
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baseline variables and percentages of categorical variables
were identical between all cohorts from the two pooled
GXR trials and ATX trial; in addition, placebo group
efficacy results were matched exactly between the GXR
and ATX trials.
Results from the unadjusted comparisons of the base
case and associated three-trial sensitivity analyses are
shown in Table 2. Unadjusted comparisons reveal that the
placebo outcomes were different between the GXR and
ATX groups. Compared with patients on placebo in the
ATX trial, patients on placebo in the pooled GXR trials
demonstrated significantly greater reductions in mean (SE)
ADHD-RS-IV total [-4.8 (1.6); p \ 0.01] and subscale
scores [hyperactivity/impulsivity: -1.8 (0.8); p \ 0.05;
inattention: -3.1 (1.0); p \ 0.01]. This suggests that
unobserved variables (e.g., conduct of the trials, baseline
characteristics, etc.) were different between the ATX and
GXR studies and cohorts. Therefore, differences in placebo
effect from cross-trial differences in unobserved variables
were adjusted for in the MAIC model. In the base-case
[target doses of GXR (0.09–0.12 mg/kg/day) and ATX
(1.2 mg/kg/day)] unadjusted comparison before matching,
GXR-treated patients demonstrated better efficacy (as
shown by statistically significantly greater reductions in
mean change from baseline for ADHD-RS-IV total score
and subscale scores for hyperactivity/impulsivity and
inattention) compared with ATX-treated patients.
After matching for baseline characteristics and differ-
ences in the placebo effect across treatments, the MAIC base
case analysis confirmed significantly greater reductions for
patients receiving GXR 0.09–0.12 mg/kg/day compared
with ATX-treated patients in mean (SE) ADHD-RS-IV total
score [-7.0 (2.2); p \ 0.01] and subscale scores for hyper-
activity/impulsivity [-3.8 (1.2); p \ 0.01] and inattention
[-3.2 (1.3); p \ 0.05; Fig. 3]. Patients receiving a lower
dose range of GXR (0.075–0.090 mg/kg/day) demonstrated
significantly greater reductions in ADHD total score and in
the hyperactivity/impulsivity subscale score compared with
ATX-treated patients; patients receiving 0.046–0.075 mg/
kg/day GXR demonstrated significantly greater reductions in
the ADHD-RS-IV inattentive subscale score compared with
ATX-treated patients (Fig. 3).
In the six-trial sensitivity analysis, before matching,
patients receiving the target GXR dose (0.09–0.12 mg/kg/
day) demonstrated significantly greater reductions versus
ATX in mean ADHD-RS-IV total score, as well as subscale
scores for hyperactivity/impulsivity and inattention,
respectively (Table 3). As noted in the base case analysis,
patients receiving placebo in the pooled GXR trials also
demonstrated significantly greater reductions in ADHD-RS-
IV total and subscale scores compared with patients receiv-
ing placebo in the pooled ATX trials. After matching, GXR
patients in the target dose range (0.09–0.12 mg/kg/day)
demonstrated significantly greater reductions over ATX in
Table 2 Unadjusted comparison of change from baseline at final on-treatment assessment in ADHD-RS-IV scores: three-trial base case and
dosage range sensitivity analyses
Change in ADHD-RS-IV score, mean (SE) GXR trials ATX trial (1.2 mg/kg/day) Comparison (GXR vs. ATX)
Placebo, n 136 83
Total score -10.6 (1.1) -5.8 (1.2) -4.8 (1.6)**
Hyperactivity/impulsivity subscale score -5.0 (0.6) -3.2 (0.6) -1.8 (0.8)*
Inattention subscale score -5.6 (0.6) -2.5 (0.7) -3.1 (1.0)**
GXR 0.09–0.12 mg/kg/day, n 82 84
Total score -22.8 (1.3) -13.6 (1.5) -9.2 (2.0)**
Hyperactivity/impulsivity subscale score -11.5 (0.7) -6.6 (0.8) -4.9 (1.0)**
Inattention subscale score -11.3 (0.7) -7.0 (0.9) -4.3 (1.1)**
GXR 0.075–0.090 mg/kg/day, n 46 84
Total score -18.5 (2.1) -13.6 (1.5) -4.9 (2.6)
Hyperactivity/impulsivity subscale score -9.4 (1.1) -6.6 (0.8) -2.8 (1.3)*
Inattention subscale score -9.1 (1.2) -7.0 (0.9) -2.1 (1.5)
GXR 0.046–0.075 mg/kg/day, n 147 84
Total score -17.9 (1.1) -13.6 (1.5) -4.3 (1.9)*
Hyperactivity/impulsivity subscale score -8.4 (0.6) -6.6 (0.8) -1.8 (1.0)
Inattention subscale score -9.4 (0.6) -7.0 (0.9) -2.4 (1.1)*
ADHD attention-deficit/hyperactivity disorder, ADHD-RS-IV ADHD Rating Scale IV, ATX atomoxetine, GXR guanfacine extended release, SE
standard error
* p \ 0.05 for comparisons between GXR vs. ATX trials
** p \ 0.01 for comparisons between GXR vs. ATX trials
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mean (SE) ADHD-RS-IV total score [-7.6 (1.4); p \ 0.01]
and subscale scores for hyperactivity/impulsivity [-4.0
(0.8); p \ 0.01] and inattention [-3.7 (0.8); p \ 0.01], as
did patients in the lowest GXR dose group (0.046–0.075 mg/
kg/day) versus ATX. The differences between GXR
0.075–0.090 mg/kg/day and ATX in mean ADHD-RS-IV
total and subscale scores were not statistically significant
(Fig. 4).
4 Discussion
The purpose of CER is ‘‘to improve health outcomes by
developing and disseminating evidence-based information
to patients, clinicians, and other decision-makers,
responding to their expressed needs, about which inter-
ventions are most effective for which patients under spe-
cific circumstances’’ [19]. Such evidence-based
information is important to clinicians, patients, payers and
policymakers in determining treatment decisions and best
practices. In 2009, the American Recovery and Reinvest-
ment Act (ARRA) set aside more than US$1 billion to fund
CER projects [19], highlighting the overall need for com-
parative evidence. It appears that CER will continue in the
future, as the 2010 Patient Protection and Affordable Care
Act was passed, building on the funding initiated by the
ARRA by providing new and increased funding for CER
until 2019 that will reach an annual total of US$600 million
during this time period [20]. With this in mind, a cost-
effective approach for generating CER data would be to
leverage available clinical trial data at the individual
patient level.
MAIC overcomes limitations of unadjusted ITC meth-
ods by utilizing IPD, to compare treatment outcomes across
balanced populations. The utility of MAIC has been
demonstrated in a number of other therapeutic areas, such
as psoriasis, newly diagnosed chronic myelogenous leu-
kemia, and type 2 diabetes [9].
With IPD available from GXR clinical trials, it was
possible to select a specific group of patients given equi-
potent (based on mg/kg/day) doses and compare them with
patients in the target (maximum effective) dose ATX trials.
In the present analysis, the unadjusted comparisons
revealed significantly larger decreases in ADHD-RS-IV
scores with GXR at the target dose compared with ATX.
However, patients in the placebo arm of the GXR trials
also revealed significantly larger decreases in ADHD
symptom scores compared with ATX. The apparent
decreases in ADHD-RS-IV total and subscale scores in this
unadjusted analysis may be impacted by baseline differ-
ences between the GXR and ATX cohorts as well as dif-
ferences in placebo effect. Re-weighting of IPD using
MAIC methodology allowed for exact matching of average
baseline characteristics of age, sex, and baseline ADHD-
RS-IV scores across cohorts. Although the cohorts were not
significantly different in all baseline variables to begin
with, it should be noted that even non-statistically signifi-
cant baseline differences can lead to significant con-





































































































































c Inattention subscale scores
Fig. 3 Matching-adjusted indirect comparison of change from base-
line at final on-treatment assessment in ADHD-RS-IV scores: three-
trial base case and sensitivity analyses. ADHD attention-deficit/
hyperactivity disorder, ADHD-RS-IV ADHD Rating Scale IV, ATX
atomoxetine, GXR guanfacine extended release, SE standard error.
*p \ 0.05 compared with ATX. **p \ 0.01 compared with ATX
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for baseline differences and placebo arm response rates,
patients on the target dose of GXR demonstrated signifi-
cantly better efficacy compared with patients on the target
dose of ATX in ADHD symptom reduction. Results of
sensitivity analyses were consistent across a range of GXR
doses below the target dose when compared with ATX
doses at the target dose or higher, confirming the gener-
alizability of the base case comparison to a broader and
more heterogeneous trial population which may be clini-
cally relevant.
Our results demonstrate that, on average, GXR is more
efficacious than ATX for the treatment of ADHD in chil-
dren and adolescents; these results demonstrated consistent
significant reductions in symptoms in GXR over ATX in
the base case analysis and in several of the sensitivity
analyses. In the MAIC base case analysis, we observed an
average reduction in ADHD-RS-IV total score of 7.0 for
GXR compared with ATX. Similarly, in the six-trial sen-
sitivity analysis, a significant reduction in ADHD-RS-IV
total score of 7.6 points more for GXR compared with
ATX was observed. An analysis by Zhang et al. [21]
defined a between-treatment minimal clinically important
difference for ADHD-RS-IV total scores as 6.6 points; this
suggests that the *7 point reduction in ADHD-RS-IV total
score on GXR compared with ATX demonstrated by the
MAIC analyses is not only statistically significant but may
also be clinically meaningful. The potential clinical impact
of these statistically significant differences should be
explored further. Also, some researchers have attempted to
correlate ADHD-RS-IV scores with scores on the Clinical
Global Impressions-Improvement (CGI-I) and CGI-S
scales, which correspond to global judgments regarding
disease severity made by clinicians in practice [22]. In an
evaluation of ADHD clinical trials of the effect of lis-
dexamfetamine dimesylate (Vyvanse; Shire LLC, Wayne,
PA, USA), Goodman et al. [22] found that differences in
ADHD-RS-IV total score of 8–10 points were approxi-
mately correlated to a 1-level difference in CGI-S severity
[e.g., from 4 (moderately ill) to 3 (mildly ill)]. However,
the generalizability of those results to the current analysis
of GXR and ATX is not known.
Our analysis has several limitations. As shown in Fig. 1,
92 trials (82 ATX and ten GXR) were assessed for eligi-
bility, but the majority had to be excluded for a variety of
reasons. For example, one trial [23] contained a study
population that met the criteria for inclusion into our study;
however, the paper did not report mean baseline ADHD-
RS-IV total scores (required for MAIC) and therefore could
not be used. Had more clinical trials been available for
inclusion, different results might have been obtained. As is
the case in any comparison of nonrandomized treatment
groups, including MAIC, cross-trial differences in unob-
served characteristics could have biased the comparison of
outcomes. Only a direct treatment comparison through a
Table 3 Unadjusted comparison of change from baseline at final on-treatment assessment in ADHD-RS-IV scores: six-trial sensitivity analysis
Change in ADHD-RS-IV score, mean (SE) GXR trials ATX trials (C1.2 mg/kg/day) Comparison (GXR vs. ATX)
Placebo, na 136 348
Total score -10.6 (1.1) -5.8 (0.6) -4.8 (1.3)**
Hyperactivity/impulsivity subscale score -5.0 (0.6) -2.7 (0.3) -2.3 (0.7)**
Inattention subscale score -5.6 (0.6) -3.0 (0.3) -2.6 (0.7)**
GXR 0.09–0.12 mg/kg/day, n 82 506
Total score -22.8 (1.3) -14.6 (0.6) -8.2 (1.4)**
Hyperactivity/impulsivity subscale score -11.5 (0.7) -7.2 (0.3) -4.3 (0.8)**
Inattention subscale score -11.3 (0.7) -7.4 (0.3) -3.9 (0.8)**
GXR 0.075–0.090 mg/kg/day, n 46 506
Total score -18.5 (2.1) -14.6 (0.6) -3.9 (2.2)
Hyperactivity/impulsivity subscale score -9.4 (1.1) -7.2 (0.3) -2.2 (1.1)*
Inattention subscale score -9.1 (1.2) -7.4 (0.3) -1.6 (1.3)
GXR 0.046–0.075 mg/kg/day, n 147 506
Total score -17.9 (1.1) -14.6 (0.6) -3.3 (1.3)**
Hyperactivity/impulsivity subscale score -8.4 (0.6) -7.2 (0.3) -1.3 (0.7)
Inattention subscale score -9.4 (0.6) -7.4 (0.3) -2.0 (0.7)**
ADHD attention-deficit/hyperactivity disorder, ADHD-RS-IV ADHD Rating Scale IV, ATX atomoxetine, GXR guanfacine extended release, SE
standard error
* p \ 0.05 for comparisons between GXR vs. ATX trials
** p \ 0.01 for comparisons between GXR vs. ATX trials
a Sample sizes for ATX trials were based on patients with reported efficacy
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randomized trial could potentially avoid bias due to
unobserved characteristics through to randomization and
blinding. However, the fact that the average placebo effect
was also matched reduces this concern. Another potential
limitation is that the MAIC, like any adjustment procedure,
reduces the effective sample size compared with the
unmatched trial populations. This is an unavoidable
consequence of reducing variation between the different
treatment groups. In addition, while the MAIC utilized
IPD, the comparison between GXR and ATX was made at
the population level. While our results show that GXR is
more efficacious than ATX on average in the studied
populations, particular individuals or subgroups may be
more or less responsive to, or intolerant of, either medi-
cation. Individual responses indeed vary, and some indi-
vidual patients may have better outcomes with ATX.
Further patient-centered research would be necessary to
better define patient characteristics associated with medi-
cation efficacy, including who may be a responder to GXR
but not ATX and vice versa. As patient-centered medicine
with a more personalized approach evolves, the MAIC
method will be able to be potentially applied in subgroups
to further help address such issues of patient heterogeneity.
Also, an analysis of safety and tolerability with GXR
versus ATX, while an important clinical consideration for
treatment selection, was outside the scope of this CER.
Additionally, the current study focuses on the short-term
efficacy comparison between GXR and ATX. As ADHD is
a chronic condition that may require long-term treatment,
future research is needed to assess the long-term impact of
these treatments. Lastly, our analysis compared GXR and
ATX; CER studies using MAIC methodology between
clonidine extended-release and either GXR or ATX have
not yet been conducted to our knowledge.
5 Conclusions
Using the MAIC method, adjustments for observable cross-
trial differences at baseline were made using IPD. Com-
pared with patients administered ATX at the target dose of
1.2 mg/kg/day, patients administered GXR at the target
dose of 0.09–0.12 mg/kg/day demonstrated statistically
significant and clinically meaningful mean reductions from
baseline in ADHD-RS-IV total and subscale scores [21].
Results were consistent across several sensitivity analyses,
demonstrating the results’ generalizability to a wider more
heterogeneous trial population.
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c Inattention subscale scores
Fig. 4 Matching-adjusted indirect comparison of change from base-
line at final on-treatment assessment in ADHD-RS-IV scores: six-trial
sensitivity analysis. ADHD attention-deficit/hyperactivity disorder,
ADHD-RS-IV ADHD Rating Scale IV, ATX atomoxetine, GXR
guanfacine extended release, SE standard error. *p \ 0.05 compared
with ATX. **p \ 0.01 compared with ATX
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